{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Acumen Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"ABOS"},"Address":{"label":"Address","value":"427 PARK STREET, CHARLOTTESVILLE, Virginia, 22902, United States"},"Phone":{"label":"Phone","value":"+1 434 297-1000"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what we believe to be a key underlying cause of Alzheimer's disease. The company's lead drug candidate, ACU193, is a subclass monoclonal antibody which selectively targets amyloid-beta oligomers."},"CompanyUrl":{"label":"Company Url","value":"https://www.acumenpharm.com"},"KeyExecutives":{"label":"Key Executives","value":[]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}